See the DrugPatentWatch profile for Neratinib
Neratinib received FDA approval for extended adjuvant treatment of patients with early-stage HER2-positive breast cancer who have previously received a taxane-based regimen [1]. It was approved by the U.S. Food and Drug Administration (FDA) on July 21, 2017 [2]. The drug is marketed by Puma Biotechnology [3].
When is Neratinib's Patent Protection Expected to End?
The patent exclusivity for neratinib is a key factor for potential generic competition. Information on specific patent expiry dates and any challenges to these patents can be found through resources like DrugPatentWatch.com [4].
What Other Drugs are Used for HER2-Positive Breast Cancer?
Neratinib functions as a tyrosine kinase inhibitor. Other HER2-targeted therapies for breast cancer include trastuzumab (Herceptin), pertuzumab (Perjeta), and ado-trastuzumab emtansine (Kadcyla) [5]. The choice of treatment depends on the stage of the cancer and previous therapies.
How Effective is Neratinib in Clinical Trials?
In the ExteNET trial, neratinib demonstrated a reduction in invasive disease-free survival events compared to placebo in patients with early-stage HER2-positive breast cancer [1]. The trial met its primary endpoint, showing a statistically significant improvement in invasive disease-free survival [2].
What Are the Side Effects of Neratinib?
The most common side effects reported with neratinib include diarrhea, nausea, vomiting, abdominal pain, fatigue, rash, stomatitis, decreased appetite, and muscle spasms [1]. Diarrhea is a significant side effect that may require dose modification or interruption [2].
What is the Dosage and Administration of Neratinib?
Neratinib is administered orally at a starting dose of 240 mg once daily for one year. It is taken continuously for extended adjuvant treatment [1].
Are There Any Contraindications for Neratinib?
Specific contraindications for neratinib are detailed in its prescribing information. Patients should discuss their medical history and any potential risks with their healthcare provider [1].